Hope Rugo, MD

Phone: 415-353-7070
UCSF Box: 1710
Email: hrugo@medicine.ucsf.edu
UCSF Profile

Project Sponsor Location(s) Topics Start End
CC#14952: Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors Merck and Co., Inc. United States Cancer/Oncology, Pharmacology and Drug Treatment
The Breast Cancer Clinical Trials Consortium Johns Hopkins University United States Cancer/Oncology, Women's Health
Phase III Study Evaluating Palbociclib (PD-0332991), a Cycline-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone-Receptor-Positive, HER2-Normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy "Penelope" United States Cancer/Oncology, Women's Health
A Phase II, Open Study of the Clinical Activity, Safety and Tolerability of Lapatinib in Combination with Bevacizumab in Subjects with Advanced or Metastatic ErbB-2-Overexpressing Breast Cancer GlaxoSmithKline United States Cancer/Oncology, Women's Health
A Phase I/II Study Evaluating Microwave Hyperthermia and Thermodox (Lyso-Thermosensitive Liposomal Doxorubicin) in Patients with Breast Cancer Recurrence at the Chest Wall (DIGNITY) Celsion Corporation United States Cancer/Oncology, Women's Health
A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-Optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients with Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence MacroGenics, Inc. United States Cancer/Oncology
Phase 3 study of PD-0332991 (Oral CDK4/6 inhibitor) plus Letrozole versus placebo plus Letrozole for postmenopausal women with ER (+), HER2 (-) breast cancer who have not received prior systemic anti cancer therapies Pfizer United States Cancer/Oncology, Women's Health
Phase 3 trial Of Fulvestrant with or without Palbociclib +/- Goserelin in women with hormone receptor-positive, Her2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy PAREXEL International Corporation United States Cancer/Oncology, Women's Health
A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 Administered to Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer. BioMarin Pharmaceutical, Inc. United States Cancer/Oncology
Phase II, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutumide with Trastuzumab in Subjects with Her2+ AR+ Metastatic or Locally Advanced Breast Cancer Astellas Pharma, Inc. United States Cancer/Oncology, Women's Health
A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy BioMarin Pharmaceutical, Inc. United States Cancer/Oncology, Pharmacology and Drug Treatment
Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic HER2-Negative Breast Cancer. inVentiv Health Clinical, LLC United States Cancer/Oncology, Women's Health
Phase 1b/2 Study of MLN0128 (Dual TORC 1/2 Inhibitor) with Exemestane or Fulvestrant Therapy in Postmenopausal with ER+/HER2- Advanced or Metastatic Breast Cancer that has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestra Quintiles, Inc United States Cancer/Oncology, Women's Health
A Phase 2 Study of LY2835219 for Patients with Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Eli Lilly and Company United States Cancer/Oncology, Women's Health
Clinical Performance, Efficacy and Safety of the DigniCap System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients with Early Stage Breast Cancer United States Cancer/Oncology
Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study- TBCRC 029 Johns Hopkins University Egypt; Greece; Mexico; Peru Cancer/Oncology
A Phase 2, Randomized, Open-Label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients with FGF Aberrant Metastatic Breast Cancer United States Cancer/Oncology, Women's Health
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with Her2 Positive (Her2+) Metastatic Breast Cancer Genentech, Inc. United States Cancer/Oncology, Women's Health
Project Sponsor Location(s) Topics Start End
A Phase II Clinical Trial of Pembrolizumab as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) Merck Sharp & Dohme Corp United States Cancer/Oncology
Open-Label, Expanded Access Protocol of BSI-201 in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer BiPar Sciences, Inc. United States Cancer/Oncology, Women's Health
Chronic Effects of Chemotherapy on Brain Function Lawrence Berkeley National Laboratory United States
BEACON Study (BrEAst Cancer Outcomes with NKTR-102): Phase 3 Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with Anthracycline, a Taxane and Capecitabine Nektar Therapeutics United States Cancer/Oncology, Pharmacology and Drug Treatment, Women's Health
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available ImClone Systems, Inc. United States Cancer/Oncology
Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene Novartis Pharma AG United States Cancer/Oncology
Beacon (Breast Cancer Outcomes with Nktr-102): a Phase 3 Study of Nktr-102 Versus Treatment of Physician's Choice in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline, Taxane and Capecitabine Nektar Therapeutics United States Cancer/Oncology, Women's Health
A Phase II, Single Arm Study of the Use of Steroid-Based Mouthwash to Prevent Stomatitis in Postmenopausal Women with Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated with Everolimus plus Exemestane. Novartis Pharma AG United States Cancer/Oncology, Women's Health
Cellular mechanisms of resistance to chemotherapy and the impact of immune modulating therapy, and molecular characterization of circulating tumor cells (CTCs) in patients with advanced breast cancer (ABC) United States Cancer/Oncology, Women's Health
Master Member Agreement: Translational Breast Cancer Research Consortium Johns Hopkins University Egypt; Greece; Mexico; Peru Cancer/Oncology, Epidemiology and Surveillance
Genetic Determinants of Capecitabine Toxicity Johns Hopkins University United States Genetics, Pharmacology and Drug Treatment
The Breast Cancer Clinical Trials Consortium Johns Hopkins University United States Cancer/Oncology, Women's Health
Enhancing the Efficacy of Chemotherapy in Triple Negative/Basal-like Breast Cancer by Targeting Macrophages Oregon Health Sciences University United States Cancer/Oncology
Phase II study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer Novartis Pharma AG United States Cancer/Oncology
An Open-Label, Multicenter Extension Study of Trastuzumab-MCC-DM1 in Patients Previously Treated with T-DM1 in a Genentech-Sponsored T-DM1 Study Genentech, Inc. United States Cancer/Oncology, Women's Health
A Phase 2 Pilot Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma. United States Cancer/Oncology, Women's Health